Skip to main content
Erschienen in: Reactions Weekly 1/2021

01.02.2021 | Clinical study

Risk of PD-1- and PD-L1-inhibitor-related pneumonia

Erschienen in: Reactions Weekly | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Excerpt

Programmed cell death-1 (PD-1) and programmed cell death ligand-1(PD-L1) inhibitor therapy increases the risk of pneumonia in patients with non-small cell lung cancer (NSCLC), according to findings of a systematic review and meta-analysis published in the European Journal of Clinical Pharmacology. …
Literatur
Zurück zum Zitat Tong ZQ, et al. Incidence risk of PD-1/PD-L1-related pneumonia and diarrhea in non-small cell lung cancer (NSCLC) patients: a systematic review and meta-analysis of randomized controlled trials. European Journal of Clinical Pharmacology : 10 Feb 2021. Available from: URL: http://doi.org/10.1007/s00228-020-03083-9 Tong ZQ, et al. Incidence risk of PD-1/PD-L1-related pneumonia and diarrhea in non-small cell lung cancer (NSCLC) patients: a systematic review and meta-analysis of randomized controlled trials. European Journal of Clinical Pharmacology : 10 Feb 2021. Available from: URL: http://​doi.​org/​10.​1007/​s00228-020-03083-9
Metadaten
Titel
Risk of PD-1- and PD-L1-inhibitor-related pneumonia
Publikationsdatum
01.02.2021
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2021
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-021-91111-6

Weitere Artikel der Ausgabe 1/2021

Reactions Weekly 1/2021 Zur Ausgabe

Case report

Bleomycin

Case report

Antineoplastics

Case report

Atezolizumab